Tomš J, Daňková M, Hrnčíř Z 2 nd Department of Medicine
description
Transcript of Tomš J, Daňková M, Hrnčíř Z 2 nd Department of Medicine
Patients with Rheumatoid Arthritis Patients with Rheumatoid Arthritis
in Comparison to in Comparison to
Other Connective Tissue Diseases Other Connective Tissue Diseases
Are Mostly Influenced by Are Mostly Influenced by
Concomitant FibromyalgiaConcomitant Fibromyalgia
Tomš J, Daňková M, Hrnčíř ZTomš J, Daňková M, Hrnčíř Z22ndnd Department of Medicine Department of Medicine
Faculty of Medicine and University HospitalFaculty of Medicine and University Hospital
Hradec Králové, Czech republicHradec Králové, Czech republic
Abstract
Background: A number of clinical studies documented that fibromyalgia (FM) can frequently accompany connective tissue diseases (CTD) as a concomitant syndrome. There is a lack of data about differencies in FM impact on individual CTD.
Objectives: To compare the impact of concomitant FM on CTD in terms of pain intensity, disease activity, function disability and quality of life (QOL) in a regional, monocentric, cross-sectional study.
Methods: 120 consecutive patients (pts) with rheumatoid arthritis (RA), 91 pts with systemic lupus (SLE), 30 pts with polymyositis/dermatomyositis (PM/DM) and 30 pts with systemic sclerosis (SSc) were examined in our outpatient rheumatology department on the presence of FM (ACR criteria,1990). Standard Manual Tender Point Survey was used for the examination of FM tender points. The following data were recorded: demographic data, tender point count (TPC), pain, fatigue and stiffness intensity on a 100 mm visual analog scale (VAS), Fibromyalgia Impact Questionnarie (FIQ) score and disease activity indices according to individual CTD representatives (DAS-28, SLEDAI, serum muscle enzymes). Health Assessment Questionnarie (HAQ) and Short Form 36 items (SF-36) were used for evaluation of functional disability and QOL, respectively. Statistical analysis was based on Kruskal-Wallis nonparametric tests comparing mutually all the CTD cohorts with and without FM. Patient file with SSc and FM was not included into the analysis due to small quantity.
Results: FM diagnosis was established in 25 (20.8%) pts with RA, 10 (11.0%) pts with SLE, 4 (13.3%) pts with PM/DM and 1 patient with SSc (3.6%). CTD groups with concomitant FM were shown to have significantly higher levels of pain, fatigue, stiffness, TPC and FIQ (p <0.05). RA/FM pts reached the highest average intensity of pain (VAS pain 63.7 mm), the worst disability level (HAQ 1.832) and the most reduced QOL in some of SF-36 domains. Disease activity assessment was significantly influenced only in RA pts (DAS-28 in RA with and without FM 5.35 1.1 vs. 3.67 1.4; p < 0.0001).
Conclusion: Concomitant FM appears most frequently in pts with RA in comparison to other CTD. RA patients are also mostly influenced by FM at the level of pain perception, disability and QOL. This FM impact contributes to significant difficulties in RA disease activity assessment unlike other CTD.
Background and Objectives
Background
A number of clinical studies documented that fibromyalgia (FM) can frequently accompany connective tissue diseases (CTD) as a concomitant syndrome (Table). There is a lack of data about differencies in FM impact on individual CTD.
Objectives
To compare the impact of concomitant FM on connective tissue diseases in terms of pain intensity, disease activity, fucntion disability and quality of life in regional, monocentric, cross-sectional study.
Rheumatoid arthritis
Systemic lupus erythematodes
Poly-/ dermato- myositis
Systemic sclerosis
Sjögren syndrome
Frequency of concomitant fibromyalgia in CTD (%)
6.6 – 57.0 1.0 – 25.0 8,0 – 13.3 1.0 - 4.0 6.9 – 22.0
Methods
• clinical examination of the patients with CTD attending outpatient rheumatology department (terciary centre)
• diagnosis of RA according to the criteria ACR 1987, SLE according to the criteria ACR 1982/1997, PM/DM according to Bohan´s and Peter´s criteria (1975), SSc according to the criteria ACR 1980
• examination focused on the presence of FM according to the criteria ACR 1990• FM tender point examination - the protocol MTPS (Standardised Manual Tender Point Survey) Okifuji et al. J Rheumatol 1997;24:377-83
• disease activity - DAS-28, SLEDAI, creatinkinase (myoglobin)• functional disability - HAQ (Health assessment questionnaire)• quality of life - SF-36 (Short Form 36 items)• FIQ (Fibromyalgia Impact Questionnaire)• SDS (Zung´s self-rating depression scale)• pain, fatigue and stiffness intenstity evaluated on a 100 mm horizontal visual analogue scale (VAS)
• statistical analysis was based on Kruskal-Wallis nonparametric tests comparing mutually all the CTD cohorts with and without FM• patient file with SSc and FM was not included into the analysis due to small quantity
Patient groups
RA SLE PM/DM SSc
n 120 9130
(PM = 18, DM = 12)30
Age (years – median, range)
57.0 (22 - 74)
43.0 (18 -75)
50.0 (19 - 74)
61.5 (41 - 76)
Sex ratio (M : F)
29 : 91 (24.2 : 75.8 %)
6 : 85 (6.6 : 93.4 %)
13 : 17 (43.3 : 56.7 %)
10 : 20 (33.3 : 66.6 %)
Disease duration (years – median,
range)
11.2 (0.1 - 57.1)
8.8 (0.3 - 36.0)
3.6 (0.3 - 21.0)
6.0 (1.0 - 25.0)
Disease activityDAS-28 4.02 ± 1.52
SLEDAI 3 (0 – 13)
CK = 2.15 µkat/l (0.55 – 30.9)
Myogl = 50.1 µkat/l (22.3 – 650.5)
Not
evaluated
Explanation: data of disease activity are median and 5th – 95th percentile
Results I.
RA/FM- RA/FM+ SLE/FM- SLE/FM+ PDM/FM- PDM/FM+ SSc/FM-
N 95 25 81 10 26 4 29
Age
(years)55.9 ± 13.6 61.4 ± 10.7 43.0 ± 14.3 44.8 ± 9.7 48.5 ± 16.8 54.3 ± 11.5 61.9 ± 9.9
Sex ratio
(M : F)25 : 70
4 : 21
6 : 75
0 : 10 13 : 13 0 : 410 : 19
Disease duration
(years)
10.9 ± 9.1 12.8 ± 12.5 10.1 ± 7.8 11.1 ± 7.0 2,5 11.2 7.1 ± 5.2
Disease activity
*DAS-28 3.67 ± 1.4
*DAS-28 5.35 ± 1.1
SLEDAI 3 (0 – 13)
SLEDAI 3.5 (0 –
9.0)
CK = 2.00 µkat/l (1.3 – 5.1)
Myogl = 52.6 µkat/l (30.0 –
135.0)
CK = 2.20 µkat/l (1.9 – 9.6)
Myogl = 37,2 µkat/l (27.0 – 96.0)
Not
Evaluated
Explanation: parameters characterized by more numbers: average ± standard deviation or median and5th-95th percentile
* Difference in DAS-28 is statistically significant: p < 0.0001
Results II.
0
10
20
30
40
50
60
70
VAS pain VAS fatigue VAS stiffness FIQ TPC
RA/FM+
RA/FM-
SLE/FM+
SLE/FM-
PDM/FM+
PMD/FM-
SSc/FM-
Explanation: CTD – connective tissue diseases, VAS - visual analogue scale, FIQ – Fibromyalgia Impact Questionnaire, TPC – tender point count
CTD groups with concomitant FM were shown to have significantly higher levels
of pain, fatigue, stiffness, TPC and FIQ (p <0.05).
RA/FM+ patients reached the highest average intensity of pain (VAS pain 63.7 mm).
Results III.
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
HAQ SDS
RA/FM+
RA/FM-
SLE/FM+
SLE/FM-
PDM/FM+
PMD/FM-
SSc/FM-
Explanation: HAQ - Health Assessment Questionnaire, SDS – Zung´s depression self-rating scale
RA/FM+ patients reached the worst disability level (HAQ 1.832), p < 0.05,and the highest depression score (SDS 0.508), p < 0.05.
p < 0,001
Values on individual axes are mean scores of quality of life domains. PF – physical functioning, RP – role physical, BP – bodily pain, GH – General health, VT – vitality, SF – social functioning, RE - role emotoinal, MH – mental health.
0
10
20
30
40
50
60
70
80PF
RP
BP
GH
VT
SF
RE
MH
RA/FM+
RA/FM-
SLE/FM+
SLE/FM-
PDM/FM+
PMD/FM-
Results IV.
Short Form 36 items (SF-36)
0
10
20
30
40
50
60
Cou
nt (
or m
m)
TJC SJC FW Pain - VAS
Components of DAS-28 index
RA
RA/FMp < 0.0001
p = 0.022
p = 0.438
p < 0.0001
Disease Activity in Rheumatoid arthritis
Explanation: DAS-28 – disease activity score evaluating 28 joints, TJC – tender joint count, SJC – swollen joint count, FW – erythrosite sedimentation rate, VAS - visual analogue scale
36
1
45
7
14
17
0%
20%
40%
60%
80%
100%
Re
lativn
í če
tno
st
(%)
DAS-28RAF+ 1 7 17
RAF- 36 45 14
< 3,2 3,2 - 5,1 > 5,1
0,0
20,0
40,0
60,0
0,0 1,0 2,0 3,0 4,0 5,0 6,0 7,0 8,0
DAS_28_RA
Rel
ativ
ni c
etno
st
0,0
20,0
40,0
60,0
0,0 1,0 2,0 3,0 4,0 5,0 6,0 7,0 8,0
DAS_28_FM
Re
lativ
ni c
etn
ost
Re
lati
ve
co
un
t
Re
lati
ve
co
un
t
Re
lati
ve
co
un
t %
Conclusion
• concomitant fibromyalgia appears most frequently
in patients with rheumatoid arthritis in comparison
to other connective tissue disease
• RA patients are mostly influenced by FM at the level
of pain perception, disability and in some domains of life
quality
• FM impact contributes to significant difficulties in RA
disease activity assessment unlike other connective
tissue diseases